The United States revealed a new drug for Alzheimer's patients today, Wednesday, affecting many, particularly the elderly. Earlier, American officials decided to approve an Alzheimer's drug that can modestly slow the disease, providing a new option for patients in the early stages of Alzheimer's, which is incurable and destructive to memory.
The U.S. Food and Drug Administration (FDA) has approved the drug "Kisonla" produced by Eli Lilly, to treat mild or early cases of dementia caused by Alzheimer's. "Kisonla" is only the second drug that has convincingly shown to delay cognitive decline in patients, following last year's approval of a similar drug from the Japanese pharmaceutical company Eisai.
The delay observed with both drugs extends to several months. Patients and their families will need to weigh this benefit against the downsides, including regular intravenous injections and potential serious side effects like brain swelling. Doctors treating Alzheimer's said that the FDA's approval of this new drug is an important step after decades of failed experimental treatments.
